Compounds > n'-(2-chloroethyl)-n-(2-(methylsulfinyl)ethyl)-n'-nitrosourea

Page last updated: 2024-12-07

n'-(2-chloroethyl)-n-(2-(methylsulfinyl)ethyl)-n'-nitrosourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N'-(2-chloroethyl)-N-(2-(methylsulfinyl)ethyl)-N'-nitrosourea: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	125952
CHEMBL ID	27414
MeSH ID	M0145950

Synonyms (10)

Synonym
n'-(2-chloroethyl)-n-(2-(methylsulfinyl)ethyl)-n'-nitrosourea
perrimustine
brn 5537700
n-(2-chloroethyl)-n'-(2-(methylsulfinyl)ethyl)-n-nitrosourea
urea, n-(2-chloroethyl)-n'-(2-(methylsulfinyl)ethyl)-n-nitroso-
n-(n'-(2-chloroethyl)-n'-nitrosocarbamoyl)-s-methylcysteamine sulfoxide
CHEMBL27414
96413-13-7
DTXSID70914524
n-(2-chloroethyl)-n'-[2-(methanesulfinyl)ethyl]-n-nitrosocarbamimidic acid

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay ID	Title	Year	Journal	Article
AID120654	Number of survivors/ number of animals tested at the dose of 40 mg/Kg, iv; 6/6	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.
AID121696	Antitumor activity was evaluated against L1210 leukemia, injected intravenously at a dose umol/kg, survivors/6	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.
AID120656	Number of survivors/ number of animals tested at the dose of 60 mg/Kg, iv; 4/6	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.
AID121697	Antitumor activity was evaluated against L1210 leukemia, injected intravenously at a dose umol/kg; infinity-50-100%survivals	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.
AID120658	Number of survivors/ number of animals tested at the dose of 80 mg/Kg, iv; 0/6	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.
AID120647	Number of survivors/ number of animals tested at the dose of 20 mg/Kg, iv; 0/6	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.
AID121695	Antitumor activity was evaluated against L1210 leukemia, injected intravenously at a dose umol/kg	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (50.00)	18.7374
1990's	3 (37.50)	18.2507
2000's	1 (12.50)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.85 (24.57)
Research Supply Index	2.30 (2.92)
Research Growth Index	4.16 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.85)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
ethylene chlorohydrin Ethylene Chlorohydrin: Used as a solvent, in the manufacture of insecticides, and for treating sweet potatoes before planting. May cause nausea, vomiting, pains in head and chest, stupefaction. Irritates mucous membranes and causes kidney and liver degeneration.. chloroethanol : An organochlorine compound that is ethanol substituted by at least one chloro group.	1.97	1	0	chloroethanol	xenobiotic metabolite
cysteamine Cysteamine: A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS.. cysteamine : An amine that consists of an ethane skeleton substituted with a thiol group at C-1 and an amino group at C-2.	3.36	7	0	amine; thiol	geroprotector; human metabolite; mouse metabolite; radiation protective agent
ethylnitrosourea Ethylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-ethyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by ethyl and nitroso groups.	1.97	1	0	N-nitrosoureas	alkylating agent; carcinogenic agent; genotoxin; mutagen
n'-(2-chloroethyl)-n-(2-(methylsulfonyl)ethyl)-n'-nitrosourea N'-(2-chloroethyl)-N-(2-(methylsulfonyl)ethyl)-N'-nitrosourea: structure given in first source	2.66	3	0
n,n'-bis((2-chloroethyl)nitrosocarbamoyl)cystamine N,N'-bis((2-chloroethyl)nitrosocarbamoyl)cystamine: structure given in first source	2.37	2	0
phosphatidylcholines Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.	2.01	1	0	1,2-diacyl-sn-glycero-3-phosphocholine
guanine [no description available]	1.97	1	0	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
n(7)-hydroxyethylguanine [no description available]	1.97	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Leukemia L 1210 [description not available]	0	2.37	2	0
B16 Melanoma [description not available]	0	2.01	1	0
Bone Marrow Diseases Diseases involving the BONE MARROW.	0	1.98	1	0
Metastase [description not available]	0	1.98	1	0
Benign Neoplasms [description not available]	0	1.98	1	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	1.98	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	1.98	1	0
Malignant Melanoma [description not available]	0	1.97	1	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	0	1.97	1	0
Experimental Neoplasms [description not available]	0	1.96	1	0